RU2019138773A - Производство транс-[тетрахлорбис(1h-индазол)рутената(iii)] и его композиций - Google Patents

Производство транс-[тетрахлорбис(1h-индазол)рутената(iii)] и его композиций Download PDF

Info

Publication number
RU2019138773A
RU2019138773A RU2019138773A RU2019138773A RU2019138773A RU 2019138773 A RU2019138773 A RU 2019138773A RU 2019138773 A RU2019138773 A RU 2019138773A RU 2019138773 A RU2019138773 A RU 2019138773A RU 2019138773 A RU2019138773 A RU 2019138773A
Authority
RU
Russia
Prior art keywords
composition
iii
hind
trans
constitutes
Prior art date
Application number
RU2019138773A
Other languages
English (en)
Russian (ru)
Other versions
RU2019138773A3 (https=
Inventor
Томас ВОЙКОВСКИ
Кевин СИЛЛ
Адам КЭРИ
Original Assignee
Интезайн Текнолоджис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Интезайн Текнолоджис, Инк. filed Critical Интезайн Текнолоджис, Инк.
Publication of RU2019138773A publication Critical patent/RU2019138773A/ru
Publication of RU2019138773A3 publication Critical patent/RU2019138773A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046Ruthenium compounds
    • C07F15/0053Ruthenium compounds without a metal-carbon linkage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2019138773A 2017-05-05 2018-05-07 Производство транс-[тетрахлорбис(1h-индазол)рутената(iii)] и его композиций RU2019138773A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762501984P 2017-05-05 2017-05-05
US62/501,984 2017-05-05
PCT/US2018/031436 WO2018204930A1 (en) 2017-05-05 2018-05-07 Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof

Publications (2)

Publication Number Publication Date
RU2019138773A true RU2019138773A (ru) 2021-06-08
RU2019138773A3 RU2019138773A3 (https=) 2022-02-01

Family

ID=64016742

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019138773A RU2019138773A (ru) 2017-05-05 2018-05-07 Производство транс-[тетрахлорбис(1h-индазол)рутената(iii)] и его композиций

Country Status (11)

Country Link
US (5) US10611787B2 (https=)
EP (3) EP4245305B1 (https=)
JP (4) JP7183253B2 (https=)
CN (2) CN117462558A (https=)
AU (2) AU2018263965B2 (https=)
CA (1) CA3062369A1 (https=)
ES (1) ES2959891T3 (https=)
PL (1) PL3618827T3 (https=)
RU (1) RU2019138773A (https=)
SG (1) SG11201910043PA (https=)
WO (1) WO2018204930A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201910043PA (en) 2017-05-05 2019-11-28 Intezyne Technologies Inc Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof
WO2021108923A1 (en) * 2019-12-05 2021-06-10 Bold Therapeutics Inc. Combined use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] and etomoxir for treating cancers
WO2021195763A1 (en) * 2020-03-30 2021-10-07 Bold Therapeutics Inc. Antiviral ruthenate(iii) therapeutics
EP4247413A4 (en) * 2020-11-18 2024-10-09 Bold Therapeutics Inc. USE OF SODIUM TRANS-[TETRACHLORIDOBIS(1H-INDAZOLE)RUTHENATE(III)] FOR THE TREATMENT OF CANCERS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612291A1 (de) * 1996-03-28 1997-10-02 Bernhard K Prof Dr Dr Keppler Arzneimittelzubereitungen enthaltend tumorhemmend wirkende Ruthenium(III)-Komplexe
DE10103565B4 (de) * 2001-01-26 2007-06-14 Faustus Forschungs Cie. Translational Cancer Research Gmbh Zusammensetzungen, enthaltend einen Ruthenium(III)-komplex und einen Heterocyclus
JP5296063B2 (ja) * 2007-06-11 2013-09-25 ニッキ ファーマ インク. ルテニウム錯体を製造する方法
WO2011161570A2 (en) * 2010-06-22 2011-12-29 Firmenich Sa Ruthenium based complexes
WO2012012305A2 (en) 2010-07-18 2012-01-26 Niiki Pharma Inc. Combination therapy using a ruthenium complex
BR112015023568B8 (pt) 2013-03-15 2024-01-02 Ann Mcfarland Sherri Composto à base de metal como composto fotodinâmico
CN103601759B (zh) * 2013-10-18 2015-08-19 武汉利宝瑞医药科技有限公司 一种用于治疗肿瘤的钌(iii)络合物的制备方法
EP3313392B1 (en) 2015-06-23 2020-09-16 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
SG11201910043PA (en) * 2017-05-05 2019-11-28 Intezyne Technologies Inc Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof

Also Published As

Publication number Publication date
JP2025123344A (ja) 2025-08-22
CA3062369A1 (en) 2018-11-08
US12415825B2 (en) 2025-09-16
JP2020518676A (ja) 2020-06-25
US20230357297A1 (en) 2023-11-09
AU2024203511A1 (en) 2024-06-20
AU2018263965B2 (en) 2024-02-29
SG11201910043PA (en) 2019-11-28
EP4245305A2 (en) 2023-09-20
JP2024045436A (ja) 2024-04-02
US20180327435A1 (en) 2018-11-15
WO2018204930A1 (en) 2018-11-08
JP7183253B2 (ja) 2022-12-05
ES2959891T3 (es) 2024-02-28
AU2024203511B2 (en) 2026-03-19
EP4245305B1 (en) 2025-10-08
EP4635503A3 (en) 2025-10-29
EP4245305C0 (en) 2025-10-08
EP3618827A4 (en) 2020-09-02
EP3618827A1 (en) 2020-03-11
JP7698083B2 (ja) 2025-06-24
US20260042792A1 (en) 2026-02-12
RU2019138773A3 (https=) 2022-02-01
JP7433402B2 (ja) 2024-02-19
EP3618827B1 (en) 2023-07-26
EP3618827C0 (en) 2023-07-26
JP2023016867A (ja) 2023-02-02
EP4245305A3 (en) 2023-10-04
US10611787B2 (en) 2020-04-07
PL3618827T3 (pl) 2024-01-22
EP4635503A2 (en) 2025-10-22
US20210277040A1 (en) 2021-09-09
US11040993B2 (en) 2021-06-22
US20200262855A1 (en) 2020-08-20
CN111372939B (zh) 2023-11-07
CN117462558A (zh) 2024-01-30
CN111372939A (zh) 2020-07-03
US11739111B2 (en) 2023-08-29
AU2018263965A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
RU2019138773A (ru) Производство транс-[тетрахлорбис(1h-индазол)рутената(iii)] и его композиций
JP2019524883A5 (https=)
JP2017522276A5 (https=)
JP2024516371A5 (https=)
RU2548673C3 (ru) Фармацевтическая композиция, содержащая производное хинолина
JP2019048806A5 (https=)
JP2016540742A5 (https=)
RU2016151208A (ru) Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор-пиридин-3-ил]-пиразоло[1, 5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы
JP2019535723A5 (https=)
ES2822081T3 (es) Intermediario de voriconazol y método de síntesis de voriconazol
JP2019504103A5 (https=)
JP2015523382A5 (https=)
JP2012528813A5 (https=)
JP2013526497A5 (https=)
JP2017519796A5 (https=)
JP2006151999A5 (https=)
JP2020508324A5 (https=)
JP2020518676A5 (https=)
CN101429175B (zh) 一种具有抗肿瘤活性的紫苏醇衍生物及其用途
JP2021091670A5 (https=)
JP2015512381A5 (https=)
CN101607918A (zh) 一种美托洛尔的制备方法
CN108976188B (zh) 一种艾司西酞普兰双羟萘酸盐新的制备方法
RU2018100116A (ru) Дейтерированные производные тиенопиперидина, способ их получения и применение
JP2018509421A5 (https=)